SlideShare a Scribd company logo
Diffuse Interstitial
(Infiltrative, Restrictive)
Diseases
M .Sibanda MBChB 5
Obstructive Versus Restrictive
Pulmonary Diseases
Such a classification is based on pulmonary function tests.
A critical part of the initial workup of patients.
1. obstructive disease (airway disease)- limitation of airflow.
2. restrictive disease-reduced expansion of lung parenchyma.
Obstructive disease: hallmark is a decreased expiratory flow rate (FEV1
it follows that the ratio of FEV1 to FVC ).
Diffuse restrictive diseases FVC is reduced and the expiratory flow rate
is normal or reduced proportionately (ratio of FEV1 to FVC is near
normal).
Focus on restrictive defect
Occurs in two general conditions
1. Chest wall disorders in the presence of normal lungs (e.g in diseases
of the pleura, Guillain-Barre syndrome.
2. Acute or chronic interstitial lung diseases (classic acute restrictive
disease is ARDS, Chronic restrictive diseases pneumoconiosis, interstitial
fibrosis of unknown aetiology, and most of the infiltrative conditions
(e.g., sarcoidosis).
THE SECOND CONDITION IS WHAT WE WILL FOCUS ON.
Diffuse Interstitial (Infiltrative,
Restrictive) Diseases
Heterogeneous group of disorders
characterised by diffuse usually
chronic involvement of pulmonary
connective tissue. Principally the
most peripheral and delicate
interstitium in alveolar walls
DEFINITION cont.…
Many of the entities are of unknown cause and pathogenesis.
Some have an intra-alveolar as well as an interstitial component.
Account for about 15% of non-infectious diseases.
Clinical and pulmonary functional changes.
 Patients have dyspnoea, tachypnea, end-inspiratory crackles, and
eventual cyanosis, without wheezing.
Classic physiologic features: reductions in carbon monoxide diffusing
capacity, lung volume, and compliance.
CXR-picture and the term infiltrative.
Early stages-can often be distinguished .
Advanced forms- hard to differentiate becoz, of end-stage lung.
DEFINITION cont.…
Categorized either as clinicopathologic syndromes or as having
characteristic histology .
 Frequency of disease: most common associations are
-Environmental diseases (approximately 25%)
-Sarcoidosis (approximately 20%)
-Idiopathic pulmonary fibrosis (approximately 15%)
-the collagen vascular diseases (approximately 10%)
more than 100 different causes and associations account for the
remaining interstitial disease.
Pathogenesis
Pathogenesis cont.…
Earliest common manifestation of most of the interstitial diseases is
alveolitis.
In mild and self-limited injury, resolution with restoration of normal
architecture follows.
 Accumulation of leukocytes has two consequences.
-1. Distorts the normal alveolar structures .
-2. Release of mediators that can injure parenchymal cells and
stimulate fibrosis
THESE RESULT IN END STAGE LUNG
Pathogenesis cont.…
initial stimuli for alveolitis are as heterogeneous, ROS, directly toxic to
endothelial cells, epithelial cells etc.
Compliment and macrophage mediated accumulation of
inflammatory cells is seen I most diseases .
CMI is seen in disease like sarcoidosis with formation of granulomas .
Major Categories of Chronic Interstitial Lung Disease
Fibrosing
Usual interstitial pneumonia (idiopathic pulmonary fibrosis) (IPF )
Nonspecific interstitial pneumonia (NSIP)
Cryptogenic organizing pneumonia (COP)
Associated with collagen vascular diseases
Pneumoconiosis
Drug reactions
Radiation pneumonitis
Granulomatous
Sarcoidosis
Hypersensitivity pneumonitis
Eosinophilic
Smoking-Related
Desquamative interstitial pneumonia
Respiratory bronchiolitis-associated interstitial lung disease
Other
Pulmonary alveolar proteinosis
Fibrosing Category
1. Idiopathic Pulmonary Fibrosis (cryptogenic fibrosing alveolitis)
Diffuse interstitial fibrosis (usual interstitial pneumonia (UIP)), which in
advanced cases results in severe hypoxemia and cyanosis.
Males are affected more often than are females.
Approx. two-thirds of patients are older than 60 years of age at
presentation.
similar pathologic findings in the lung may be noted with well-defined
entities such as asbestosis
Morphology
Pleural surfaces of the lung have the appearance of cobblestones .
The cut surface shows fibrosis (firm, rubbery white areas).
Patchy interstitial fibrosis.
 Earliest lesions appear as fibroblastic foci .
Temporal heterogeneity.
Honeycomb fibrosis occurs.
The interstitial inflammation is usually patchy and consists of an alveolar
septal infiltrate of mostly lymphocytes .
 Foci of squamous metaplasia and Intimal fibrosis and medial thickening
of pulmonary arteries often present.
Usual interstitial pneumonia. The fibrosis, which varies in intensity, is more
pronounced in the sub-pleural region
Usual interstitial pneumonia. Fibroblastic focus with fibres running parallel to surface
and bluish myxoid extracellular matrix.
Clinical Course
IPF usually presents insidiously
Gradual onset of a non-productive cough and progressive dyspnoea.
O/E
 "dry" or "Velcro"-like crackles during inspiration.
Cyanosis, cor pulmonale, and peripheral oedema .
Investigations: Surgical lung biopsy remains the gold standard for
diagnosing IPF .
Prognosis is poor mean survival of 3 years or less.
Nonspecific Interstitial Pneumonia
Unknown aetiology, affects mostly 45 to 55 year olds.
Lung biopsies fail to show diagnostic features of any of the other well-
characterized interstitial diseases.
"wastebasket" type of diagnosis, it is important to differentiate non-
specific interstitial fibrosis from UIP.
Divided into cellular and fibrosing patterns.
Fibroblastic foci are typically absent.
Clinical course : Patients present with dyspnoea and cough of several
months' duration
cellular pattern have a better outcome
Cryptogenic Organizing
Pneumonia
Synonymous with "bronchiolitis obliterans organizing pneumonia.
Clinical course
cough and dyspnoea .
 Radiographically have subpleural or peribronchial patchy areas of
airspace consolidation
Some individuals recover spontaneously, but most require treatment
Histologically
Polypoid plugs of loose organizing connective tissue within alveolar
ducts, alveoli, and often bronchioles .
Organizing pneumonia with intra-alveolar fibrosis.
 There is no interstitial fibrosis/ honeycomb
Cryptogenic organizing pneumonia. Alveolar spaces are filled with balls of
fibroblasts (arrow).
Pulmonary Involvement in Collagen
Vascular Diseases
systemic lupus erythematous, rheumatoid arthritis, systemic sclerosis,
and dermatomyositis-polymyositis are examples.
Histologic variants , with NSIP, UIP-pattern (similar to what is seen in IPF),
vascular sclerosis, organizing pneumonia, and bronchiolitis (small
airway disease, with or without fibrosis) being the most common.
Pulmonary involvement in these diseases is usually associated with a
poor prognosis.
Pneumoconiosis
Non neoplastic lungs reaction to inhalation of mineral dusts in the work
place and organic as well as inorganic particles, fumes and vapours.
Mineral Dust-Induced Lung Disease
 Agent Disease: Exposure
Coal dust exposure: Simple coal workers' pneumoconiosis: macules and
nodules Complicated coal workers' pneumoconiosis: PMF- Coal mining
Silica exposure: Silicosis -Sandblasting, quarrying, mining, stone cutting,
foundry work, ceramics
Asbestos exposure: Asbestosis pleural effusions, pleural plaques, or diffuse
fibrosis; mesothelioma; carcinoma of the lung and larynx- Mining, milling, and
fabrication of ores and materials; installation and removal of insulation
Pathogenesis
Size, shape, solubility, and reactivity of the particles etc determine the
reaction of the lung to mineral dusts .
The amount which cause disease depends on the factors above.
Coal dust is relatively inert (large amounts must deposit).
Silica, asbestos, and beryllium are more reactive than coal dust (fibrotic
reactions at lower concentrations)
Macrophages accumulate and endocytose the trapped particulates
More reactive particles trigger the macrophages to release inflammatory
mediators.
Tobacco smoking worsens the effects of all inhaled mineral dusts, more so with
asbestos than with any other particle.
 Larger particles resist dissolution these tend to evoke fibrosing collagenous
pneumoconiosis (characteristic of silicosis).
Coal Workers' Pneumoconiosis
("black lung" )
Findings range from: 1.asymptomatic anthracosis, 2.simple coal
workers' pneumoconiosis (CWP),3. complicated CWP or progressive
massive fibrosis (PMF).
Fewer than 10% of cases of simple CWP progress to PMF.
PMF is a generic term that applies to a confluent fibrosing reaction in
the lung; this can be a complication of any one of the three
pneumoconiosis discussed here.
Anthracite mining has been associated with a higher risk of CWP.
Morphology
Pulmonary anthracosis: innocuous coal-induced pulmonary lesion
-Inhaled carbon pigment is engulfed by alveolar or interstitial macrophages.
-Which then accumulate in the connective tissue along the lymphatics,
including the pleural lymphatics, or in lymph nodes.
Linear streaks and aggregates of anthracotic pigment are seen.
Simple CWP: coal macules and the somewhat larger coal nodule are seen.
-The upper lobes and upper zones of the lower lobes are more heavily
involved.C
-Centrilobular emphysema can occur.
Complicated CWP (PMF)
Occurs on a background of simple CWP by coalescence of coal nodules
characterized by intensely blackened scars larger than 2 cm, sometimes up to
10 cm in greatest diameter
Progressive massive fibrosis superimposed on coal workers' pneumoconiosis. The large
blackened scars are principally in the upper lobe. Note the extensions of scars into
surrounding parenchyma and retraction of adjacent pleura.
Clinical Course
 Usually a benign disease that produces little decrement in lung function.
Increasing pulmonary dysfunction, pulmonary hypertension, and cor
pulmonale, seen if PMF develops.
 Progression from CWP to PMF has been linked to a variety of conditions
including coal dust exposure level and total dust burden
 Once smoking-related risk has been taken into account, there is no increased
frequency of bronchogenic carcinoma in coal miners.
Silicosis
Currently the most prevalent chronic occupational disease in the
world. Slowly progressive.
Caused by inhalation of crystalline silica.(quartz is most commonly
implicated in silicosis)
After inhalation the particles interact with epithelial cells and
macrophages.
Ingested silica particles cause activation and release of mediators by
pulmonary macrophages, including IL-1, TNF.
When mixed with other minerals, quartz has a reduced fibrogenic
effect.
Morphology
Silicotic nodules .
Microscopically, the silicotic nodule demonstrates concentrically
arranged hyalinized collagen fibers surrounding an amorphous center.
"whorled" appearance of the collagen fibres.
Polarized microscopy reveals weakly birefringent silica particles,
primarily in the center of the nodules.
Fibrotic lesions may occur in the hilar lymph nodes and pleura.
"eggshell" calcification .
Advanced silicosis seen on transection of lung. Scarring has contracted the upper lobe into a
small dark mass (arrow). Note the dense pleural thickening
Several coalescent collagenous silicotic nodules
Clinical Course
Usually detected in routine chest radiographs performed on asymptomatic
workers.(fine nodularity in the upper zones of the lung is seen)
After PMF is present the disease may be progressive, even if the person is no
longer exposed.
Many individuals with PMF develop pulmonary hypertension and cor
pulmonale,
Disease is slow to kill, but impaired pulmonary function may severely limit
activity.
Silicosis is associated with an increased susceptibility to tuberculosis.
Asbestosis and Asbestos-Related
Diseases
occupational exposure to asbestos is linked to :
(1) parenchymal interstitial fibrosis (asbestosis)
(2) localized fibrous plaques or, rarely, diffuse fibrosis in the pleura
(3) pleural effusion
(4) bronchogenic carcinoma.
(5) malignant pleural and peritoneal mesothelioma
(6) laryngeal carcinoma.
Pathogenesis
There are two distinct forms of asbestos Serpentine and amphibole.
Amphibole are more pathogenic than the serpentine chrysotile.
Asbestos causes fibrosis by interacting with lung macrophages.
Asbestos probably also functions as both a tumor initiator and a promoter.
Potentially toxic chemicals adsorbed onto the asbestos fibers undoubtedly
contribute to the pathogenicity of the fibres.
Morphology
 Marked by diffuse pulmonary interstitial fibrosis.
Asbestos bodies distinguish it from diffuse interstitial fibrosis.
 Asbestosis begins in the lower lobes and subpleurally ( In contrast to
CWP and silicosis)
 Contraction of the fibrous tissue distorts the native architecture,
creating enlarged airspaces enclosed within thick fibrous
walls.(honeycombed formation).
Pulmonary hypertension and cor pulmonale may result.
Pleural plaques (well-circumscribed plaques of dense collagen often
containing calcium.)
Uncommonly, asbestos exposure induces pleural effusions, which are
usually serous but may be bloody.
High-power detail of an asbestos body, revealing the typical beading and
knobbed ends (arrow)
Asbestosis. Markedly thickened visceral pleura covers the lateral and diaphragmatic surface
of lung. Note also severe interstitial fibrosis diffusely affecting the lower lobe of the lung
Clinical Course
Dyspnea (exertion then at rest)
Productive cough
The disease may remain static or progress to CHF, cor pulmonale, and
death
Disease manifestations more common 20 years after exposure.
The relative risk for mesotheliomas, normally a very rare tumor , is more
than 1000-fold greater.
Concomitant cigarette smoking, has no association with increased risk
of mesothelioma.
Drug- and Radiation-Induced
Pulmonary Diseases
Acute and chronic alterations in respiratory structure and function can result from
drugs.e.g
Bleomycin, an anticancer agent, causes pneumonitis and interstitial fibrosis
Amiodarone, an anti-arrhythmic agent, is also associated with pneumonitis and
fibrosis
 Radiation pneumonitis .
Acute radiation pneumonitis-fever, dyspnea out of proportion to the volume of
irradiated lung, pleural effusion, and pulmonary infiltrates. Progress to chronic
radiation pneumonitis may occur, associated with pulmonary fibrosis.
Granulomatous Diseases
Sarcoidosis -bilateral hilar lymphadenopathy or lung involvement (or
both), visible on chest radiographs, is the major presenting
manifestation .
The prevalence of sarcoidosis is higher in women than in men, BLACKS
than whites .
Sarcoidosis is one of the few pulmonary diseases with a higher
prevalence among nonsmokers.
Aetiology and Pathogenesis
Unknown but evidence points to the1. immune dysregulation in 2.
genetically predisposed individual 3. exposed to certain environmental
agents
Cell mediated response to unidentified antigen driven by CD4= helper T
cells. CMI. These accumulate In the Intra-alveolar and interstitial space.
 IL -2 and IFN-GAMMA etc from TH-1 cells, result in T-cell expansion and
macrophage activation, respectively, this eventually lead to recruitment of
additional T cells and monocytes and contribute to the formation of
granulomas.
Polyclonal hypergammaglobulinemia and anergy to common skin test
antigens occur. (TH-cell dysregulation)
Familial and racial clustering of cases and association with certain human
leukocyte antigen (HLA) genotypes (e.g., class I HLA-A1 and HLA-B8)
 Viruses, mycobacteria, Borrelia, pollen have been proposed as the inciting
agent for sarcoidosis .
Morphology
noncaseating epithelioid granuloma.
Central necrosis unusual
Granulomatous fibrous and hyaline with chronicity.
Schaumann bodies and Asteroid bodies are also seen (not pathognomonic of
sarcoidosis) .
The granulomas predominantly involve the interstitium rather than airspaces,
with some "lymphangitic" distribution tendency.
The bronchoalveolar lavage (BAL) contains abundant CD4+T cells.
Diffuse interstitial fibrosis resulting in a honeycomb lung in 5-15%.
hilar and paratracheal lymph nodes are enlarged in 75% to 90% of patients.
Morphology cont…
Skin lesions : approximately 30-50% of cases of patients.
-Erythema nodosum, the hallmark of acute sarcoidosis ( Sarcoidal granulomas are
uncommon in these lesions).
-Lupus pernio.
Involvement of the eye and lacrimal glands occurs in about one-fifth to one-half of
patients
-ocular involvement: takes the form of iritis or iridocyclitis (Corneal opacities,
glaucoma, and (less commonly) total loss of vision may then develop.
-Posterior uveal tract is also affected.
-Ocular lesions are frequently accompanied by inflammation in the lacrimal
glands sicca syndrome may occur..
Unilateral or bilateral parotitis with painful enlargement of the parotid glands in <
10%.
 Mikulicz syndrome, is also seen.
Morphology cont…
-The spleen In about three-fourths of cases it contains granulomas, in
approximately 10% it becomes clinically enlarged.
 The liver demonstrates microscopic granulomatous lesions, usually in the portal
triads.
Bone marrow is reported in as many as 40% of patients, although it rarely causes
severe manifestations. Sometimes there is hypercalcemia and hypercalciuria.
Muscle involvement : is often underdiagnosed, since it may be asymptomatic.
muscle weakness, aches, tenderness, and fatigue should prompt consideration
of occult sarcoid myositis.
Muscle biopsy could be a useful tool in the diagnosis of sarcodosis.
Characteristic sarcoid noncaseating granulomas in lung with many giant
cells
Clinical Course.
In many individuals the disease is entirely asymptomatic, discovered on routine
chest films .
bilateral hilar adenopathy or as an incidental finding at autopsy
In others, lesion to other tissues may be presenting manifestations.
In about two-thirds of symptomatic cases there is a gradual appearance of
respiratory symptoms .
Lung or lymph node biopsy are often used.
Sarcoidosis follows an unpredictable course .
65% to 70% of affected individuals recover with minimal or no residual
manifestations.
20% develop permanent lung dysfunction or visual impairment.
Of the remaining 10% to 15%, most succumb to progressive pulmonary fibrosis and
cor pulmonale.
Patients presenting with hilar lymphadenopathy alone have the best prognosis,
followed by those with adenopathy and pulmonary infiltrates.
Hypersensitivity Pneumonitis
An immunologically mediated inflammatory lung disease (allergic alveolitis).
Results from heightened sensitivity to inhaled antigens such as moldy hay .
Immunologically mediated injury occurs at the level of alveoli.
Occupational exposures are diverse, probably have very similar pathophysiology.
Several lines of evidence suggest that hypersensitivity pneumonitis is an
immunologically mediated disease.
Increased numbers of T lymphocytes of both CD4+ and CD8+ phenotype, also
indication of a type III hypersensitivity and type IV hypersensitivity against the
implicated antigen(s).
hypersensitivity pneumonitis is an immunologically mediated response to an
extrinsic antigen that involves both immune-complex and delayed-type
hypersensitivity reactions.
progression to serious chronic fibrotic lung disease can be prevented by removal
of the environmental agent.
Selected Causes of Hypersensitivity Pneumonitis
Syndrome – Exposure - Antigens
Fungal and Bacterial Antigens
-Farmer's lung - Moldy hay - Micropolyspora faeni .
-Bagassosis - Moldy pressed sugar cane (bagasse ) - Thermophilic actinomycetes.
-Maple bark disease - Moldy maple bark - Cryptostroma corticale .
-Humidifier lung - Cool-mist humidifier -Thermophilic actinomycetes, Aureobasidium
pullulans
-Malt worker's lung - Moldy barley - Aspergillus clavatus .
-Cheese washer's lung - Moldy cheese - Penicillium casei .
Insect Products
-Miller's lung - Dust-contaminated grain - Sitophilus granarius (wheat weevil) .
Animal Products
-Pigeon breeder's lung - Pigeons - Pigeon serum proteins in droppings .
Chemicals
-Chemical worker's lung - Chemical industry - Trimellitic anhydride, isocyanates .
Morphology
Patchy mononuclear cell infiltrates, demonstrated in both acute and
chronic forms of hypersensitivity pneumonitis.
 Lymphocytes predominate, but plasma cells and epithelioid cells are also
present.
In acute forms of the disease, variable numbers of neutrophils also may be
seen.
Interstitial noncaseating granulomas are present in more than two-thirds of
cases.
In advanced chronic cases, diffuse interstitial fibrosis occurs.
Interstitial fibrosis and obliterative bronchiolitis (late stages)
Intra-alveolar infiltrates in over 50%
Hypersensitivity pneumonitis, histologic appearance. Loosely
formed interstitial granulomas and chronic inflammation are
characteristic.
Clinical Course
May present either :
As a may present either as an acute reaction with fever, cough,
dyspnea, and constitutional complaints 4 to 8 hours after exposure .
As a chronic disease with insidious onset of cough, dyspnea, malaise,
and weight loss.
Temporal relationship of symptoms to exposure to the incriminating
antigen in acute rxn makes diagnosis obvious.
Pulmonary Eosinophilia
These diverse diseases are generally of immunologic origin but are incompletely
understood .
characterized by an infiltration and activation of eosinophils, the latter by elevated levels
of alveolar IL-5.
Pulmonary eosinophilia is divided into the following categories:
1. Acute eosinophilic pneumonia with respiratory failure.
-characterized by: rapid onset of fever, dyspnea, hypoxia, and diffuse pulmonary
infiltrates on chest radiograms.
2. Simple pulmonary eosinophilia (Löffler syndrome).
-characterized by transient pulmonary lesions, eosinophilia in the blood, and a benign
clinical course.
-The alveolar septa are thickened by an infiltrate containing eosinophils and
occasional
giant cells
Pulmonary Eosinophilia
3. Tropical eosinophilia
-caused by infection with microfilariae, a parasite.
4. Secondary eosinophilia,
- Seen, for example, in association with asthma, drug allergies, and certain forms of
vasculitis.
1.Idiopathic chronic eosinophilic pneumonia.
-Characterized by aggregates of lymphocytes and eosinophils within the septal walls
and the alveolar spaces, typically in the periphery of the lung fields .
-accompanied by high fever, night sweats, and dyspnea.
-Good response to corticosteroids
Smoking-Related Interstitial
Diseases
Desquamative interstitial pneumonia (DIP) and respiratory bronchiolitis are the two eg.
Accumulation of large numbers of macrophages with abundant cytoplasm
containing dusty brown pigment (Smoker's macrophages ) in the airspaces in DIP.
- The alveolar septa are thickened by a sparse inflammatory infiltrate (usually
lymphocytes), and interstitial fibrosis, when present, is mild.
- good prognosis with excellent response to steroid therapy and smoking cessation.
Respiratory bronchiolitis .
characterized by the presence of pigmented intraluminal macrophages akin to DIP,
but in a "bronchiolocentric" distribution (first- and second-order respiratory
bronchioles).
Clinical course
DIP
presents in the fourth or fifth decade of life, more common males than
females 2 : 1.
Virtually all patients are cigarette smokers.
Desquamative interstitial pneumonia. Medium-power detail of lung to demonstrate the
accumulation of large numbers of mononuclear cells within the alveolar spaces with only
mild fibrous thickening of the alveolar walls
PULMONARY ALVEOLAR
PROTEINOSIS
Pulmonary alveolar proteinosis (PAP) is a rare disease
Characterized :
-Radiologically by bilateral patchy asymmetric pulmonary opacification .
-Histologically by accumulation of acellular surfactant in the intra-alveolar and
bronchiolar spaces.
 Three distinct classes of this disease. acquired, congenital, and secondary PAP.
1. Acquired PAP is of unknown etiology.
-Without any familial predisposition; it represents 90% of all cases of PAP.
-Now considered to be autoimmune disorder and can occur post double lung
transplant
2. Congenital PAP is a rare cause of immediate-onset neonatal respiratory distress.
-Cause unclear
PULMONARY ALVEOLAR
PROTEINOSIS
1. Secondary
Uncommon
Causes include acute silicosis
Other inhalational syndromes
Immunodeficiency disorders
Malignancy
 Hematopoietic disorders
Morphology.
Characterized by a peculiar homogeneous, granular precipitate
within the alveoli.
Minimal inflammatory reaction
Causing focal-to-confluent consolidation of large areas of the lungs
with minimal inflammatory reaction.
On section, turbid flud exudes from these areas.
Marked increase in the size and weight of the lung
Pulmonary alveolar proteinosis, histologic appearance. The alveoli are
filled with a dense, amorphous, protein-lipid granular precipitate, while the
alveolar walls are normal.

More Related Content

What's hot

interstitial lung disease
interstitial lung diseaseinterstitial lung disease
interstitial lung disease
Ednalee Warnecke
 
Suppurative lung diseases, Dr Inofomoh Francisca,
Suppurative lung diseases, Dr Inofomoh Francisca, Suppurative lung diseases, Dr Inofomoh Francisca,
Suppurative lung diseases, Dr Inofomoh Francisca,
Francesca Inofomoh
 
Interstitial lung diseases
Interstitial lung diseases Interstitial lung diseases
Interstitial lung diseases
Dr.Manish Kumar
 
Respiratory lectures
Respiratory lecturesRespiratory lectures
Respiratory lectures
DOCTOR WHO
 
Lung abscess pdf
Lung abscess pdfLung abscess pdf
Lung abscess pdf
Bs. Nhữ Thu Hà
 
Pathology of respiratory system
Pathology of respiratory systemPathology of respiratory system
Pathology of respiratory system
Mansoor Tariq Samo
 
Diffuse Parenchymal Lung Diseases
Diffuse Parenchymal Lung DiseasesDiffuse Parenchymal Lung Diseases
Diffuse Parenchymal Lung DiseasesZunaira Islam
 
Approach To Interstitial Lung Diseases
Approach To Interstitial Lung DiseasesApproach To Interstitial Lung Diseases
Approach To Interstitial Lung Diseases
Ashraf ElAdawy
 
Interstitial Lung Disease
Interstitial Lung DiseaseInterstitial Lung Disease
Interstitial Lung Diseaseguest37d6e
 
Respiratory system pathology lab
Respiratory system pathology labRespiratory system pathology lab
Respiratory system pathology lab
Mohammad Ihmeidan
 
Lecture 20 diseases of respiratory system
Lecture 20 diseases of respiratory systemLecture 20 diseases of respiratory system
Lecture 20 diseases of respiratory system
Green-book
 
Intrestitial lung disease 9 5-2016
Intrestitial  lung disease 9 5-2016Intrestitial  lung disease 9 5-2016
Intrestitial lung disease 9 5-2016
pathologydept
 
approach to interstitial lung disease
approach to interstitial lung disease approach to interstitial lung disease
approach to interstitial lung disease
ikramdr01
 
LUNG ABSCESS
LUNG ABSCESSLUNG ABSCESS
LUNG ABSCESS
Dr. Roopam Jain
 
pneumosclerosis
pneumosclerosispneumosclerosis
pneumosclerosis
dr.shameer basha
 
5 5-2016 vinita
5 5-2016 vinita5 5-2016 vinita
5 5-2016 vinita
pathologydept
 
Interstial lung diseases
Interstial lung diseasesInterstial lung diseases
Interstial lung diseases
sri harish
 

What's hot (20)

interstitial lung disease
interstitial lung diseaseinterstitial lung disease
interstitial lung disease
 
Suppurative lung diseases, Dr Inofomoh Francisca,
Suppurative lung diseases, Dr Inofomoh Francisca, Suppurative lung diseases, Dr Inofomoh Francisca,
Suppurative lung diseases, Dr Inofomoh Francisca,
 
Interstitial Lung Disease
Interstitial Lung Disease Interstitial Lung Disease
Interstitial Lung Disease
 
Interstitial lung diseases
Interstitial lung diseases Interstitial lung diseases
Interstitial lung diseases
 
CT: Interstitial lung disease
CT: Interstitial lung diseaseCT: Interstitial lung disease
CT: Interstitial lung disease
 
Respiratory lectures
Respiratory lecturesRespiratory lectures
Respiratory lectures
 
Ild & old
Ild & oldIld & old
Ild & old
 
Lung abscess pdf
Lung abscess pdfLung abscess pdf
Lung abscess pdf
 
Pathology of respiratory system
Pathology of respiratory systemPathology of respiratory system
Pathology of respiratory system
 
Diffuse Parenchymal Lung Diseases
Diffuse Parenchymal Lung DiseasesDiffuse Parenchymal Lung Diseases
Diffuse Parenchymal Lung Diseases
 
Approach To Interstitial Lung Diseases
Approach To Interstitial Lung DiseasesApproach To Interstitial Lung Diseases
Approach To Interstitial Lung Diseases
 
Interstitial Lung Disease
Interstitial Lung DiseaseInterstitial Lung Disease
Interstitial Lung Disease
 
Respiratory system pathology lab
Respiratory system pathology labRespiratory system pathology lab
Respiratory system pathology lab
 
Lecture 20 diseases of respiratory system
Lecture 20 diseases of respiratory systemLecture 20 diseases of respiratory system
Lecture 20 diseases of respiratory system
 
Intrestitial lung disease 9 5-2016
Intrestitial  lung disease 9 5-2016Intrestitial  lung disease 9 5-2016
Intrestitial lung disease 9 5-2016
 
approach to interstitial lung disease
approach to interstitial lung disease approach to interstitial lung disease
approach to interstitial lung disease
 
LUNG ABSCESS
LUNG ABSCESSLUNG ABSCESS
LUNG ABSCESS
 
pneumosclerosis
pneumosclerosispneumosclerosis
pneumosclerosis
 
5 5-2016 vinita
5 5-2016 vinita5 5-2016 vinita
5 5-2016 vinita
 
Interstial lung diseases
Interstial lung diseasesInterstial lung diseases
Interstial lung diseases
 

Viewers also liked

Approach to interstitial lung disease
Approach to interstitial lung diseaseApproach to interstitial lung disease
Approach to interstitial lung disease
Nahid Sherbini
 
Radiation pneumonitis
Radiation pneumonitisRadiation pneumonitis
Radiation pneumonitis
Ashraf ElAdawy
 
Unpacking the 2010 Census (2013 Updated Version) - Part 1
Unpacking the 2010 Census (2013 Updated Version) - Part 1Unpacking the 2010 Census (2013 Updated Version) - Part 1
Unpacking the 2010 Census (2013 Updated Version) - Part 1
jzur
 
Interstitial lung diseases 2012_pdf
Interstitial lung diseases 2012_pdfInterstitial lung diseases 2012_pdf
Interstitial lung diseases 2012_pdf
Dr.Manish Kumar
 
Radiation pneumonitis and ddx
Radiation pneumonitis and ddxRadiation pneumonitis and ddx
Radiation pneumonitis and ddxDr. Lin
 
Pulmonary 2 histoplasmosis.ppt
Pulmonary 2 histoplasmosis.pptPulmonary 2 histoplasmosis.ppt
Pulmonary 2 histoplasmosis.ppt
順賢 鄭
 
Histoplasmosis
HistoplasmosisHistoplasmosis
Histoplasmosis
Javier Hernández
 
Histoplasmosis expo
Histoplasmosis  expo Histoplasmosis  expo
Histoplasmosis expo
Antonio Araujo
 
Emphysema
EmphysemaEmphysema
Emphysema
Aamir Sharif
 
Pulmonary vascular Disease
Pulmonary vascular DiseasePulmonary vascular Disease
Pulmonary vascular DiseaseEuvette Taylor
 
09.16.08: Pulmonary Vascular Disease
09.16.08: Pulmonary Vascular Disease09.16.08: Pulmonary Vascular Disease
09.16.08: Pulmonary Vascular Disease
Open.Michigan
 
Obstructive Lung Diseases
Obstructive Lung DiseasesObstructive Lung Diseases
Obstructive Lung Diseases
autumnpianist
 
Approach To Diffuse Parenchymal Lung Diseases
Approach To Diffuse Parenchymal Lung DiseasesApproach To Diffuse Parenchymal Lung Diseases
Approach To Diffuse Parenchymal Lung DiseasesGamal Agmy
 
Histoplasmosis
HistoplasmosisHistoplasmosis
Histoplasmosis
Laura Dominguez
 
Pathology of Acute Lungi Injury- Recent advances
Pathology of Acute Lungi Injury- Recent advancesPathology of Acute Lungi Injury- Recent advances
Pathology of Acute Lungi Injury- Recent advances
Dr Snehal Kosale
 
Histoplasmosis Dr. Mamani
Histoplasmosis Dr. MamaniHistoplasmosis Dr. Mamani
Histoplasmosis Dr. Mamani
imhotep359
 
Microbiologia histoplasma capsulatum
Microbiologia   histoplasma  capsulatumMicrobiologia   histoplasma  capsulatum
Microbiologia histoplasma capsulatum
Darwin Quijano
 
Histoplasma Capsulatum
Histoplasma CapsulatumHistoplasma Capsulatum
Histoplasma CapsulatumCaiah
 
4 Restrictive Lung Diseases
4 Restrictive Lung Diseases4 Restrictive Lung Diseases
4 Restrictive Lung Diseases
Yaser Ammar
 

Viewers also liked (20)

Approach to interstitial lung disease
Approach to interstitial lung diseaseApproach to interstitial lung disease
Approach to interstitial lung disease
 
Radiation pneumonitis
Radiation pneumonitisRadiation pneumonitis
Radiation pneumonitis
 
Unpacking the 2010 Census (2013 Updated Version) - Part 1
Unpacking the 2010 Census (2013 Updated Version) - Part 1Unpacking the 2010 Census (2013 Updated Version) - Part 1
Unpacking the 2010 Census (2013 Updated Version) - Part 1
 
Interstitial lung diseases 2012_pdf
Interstitial lung diseases 2012_pdfInterstitial lung diseases 2012_pdf
Interstitial lung diseases 2012_pdf
 
Radiation pneumonitis and ddx
Radiation pneumonitis and ddxRadiation pneumonitis and ddx
Radiation pneumonitis and ddx
 
Pulmonary 2 histoplasmosis.ppt
Pulmonary 2 histoplasmosis.pptPulmonary 2 histoplasmosis.ppt
Pulmonary 2 histoplasmosis.ppt
 
Histoplasmosis
HistoplasmosisHistoplasmosis
Histoplasmosis
 
Histoplasmosis expo
Histoplasmosis  expo Histoplasmosis  expo
Histoplasmosis expo
 
Emphysema
EmphysemaEmphysema
Emphysema
 
Pulmonary vascular Disease
Pulmonary vascular DiseasePulmonary vascular Disease
Pulmonary vascular Disease
 
09.16.08: Pulmonary Vascular Disease
09.16.08: Pulmonary Vascular Disease09.16.08: Pulmonary Vascular Disease
09.16.08: Pulmonary Vascular Disease
 
Obstructive Lung Diseases
Obstructive Lung DiseasesObstructive Lung Diseases
Obstructive Lung Diseases
 
Approach To Diffuse Parenchymal Lung Diseases
Approach To Diffuse Parenchymal Lung DiseasesApproach To Diffuse Parenchymal Lung Diseases
Approach To Diffuse Parenchymal Lung Diseases
 
Histoplasmosis
HistoplasmosisHistoplasmosis
Histoplasmosis
 
Pathology of Acute Lungi Injury- Recent advances
Pathology of Acute Lungi Injury- Recent advancesPathology of Acute Lungi Injury- Recent advances
Pathology of Acute Lungi Injury- Recent advances
 
Histoplasmosis Dr. Mamani
Histoplasmosis Dr. MamaniHistoplasmosis Dr. Mamani
Histoplasmosis Dr. Mamani
 
Microbiologia histoplasma capsulatum
Microbiologia   histoplasma  capsulatumMicrobiologia   histoplasma  capsulatum
Microbiologia histoplasma capsulatum
 
Histoplasma Capsulatum
Histoplasma CapsulatumHistoplasma Capsulatum
Histoplasma Capsulatum
 
4 Restrictive Lung Diseases
4 Restrictive Lung Diseases4 Restrictive Lung Diseases
4 Restrictive Lung Diseases
 
Histoplasmosis
HistoplasmosisHistoplasmosis
Histoplasmosis
 

Similar to Diffuse interstitial (infiltrative, restrictive) diseases. Pathology. mpiloe

L7 8 .interestitial lung disease
L7 8 .interestitial lung diseaseL7 8 .interestitial lung disease
L7 8 .interestitial lung disease
bilal natiq
 
Chest x ray interpretation of infections [autosaved]
Chest x ray interpretation of infections [autosaved]Chest x ray interpretation of infections [autosaved]
Chest x ray interpretation of infections [autosaved]
nidhi aggarwal
 
ild2-160503173013.pdf
ild2-160503173013.pdfild2-160503173013.pdf
ild2-160503173013.pdf
DrYaqoobBahar
 
Interstitial Lung Diseases & Pathology Of Lung In AIDS
Interstitial Lung Diseases &Pathology Of Lung In AIDSInterstitial Lung Diseases &Pathology Of Lung In AIDS
Interstitial Lung Diseases & Pathology Of Lung In AIDS
Dr Siddartha
 
DIFFUSE LUNG DISEASES.pptx
DIFFUSE LUNG DISEASES.pptxDIFFUSE LUNG DISEASES.pptx
DIFFUSE LUNG DISEASES.pptx
farkhandashaheen4
 
Community acquired pneumonia
Community acquired pneumoniaCommunity acquired pneumonia
Community acquired pneumoniaSaba Khan
 
08 respiratory restrictive
08 respiratory   restrictive08 respiratory   restrictive
08 respiratory restrictive
med_students0
 
Lung pathology 1
Lung pathology 1Lung pathology 1
Common suppurative diseases of lung- Bronchiectasis...!
Common suppurative diseases of lung- Bronchiectasis...!Common suppurative diseases of lung- Bronchiectasis...!
Common suppurative diseases of lung- Bronchiectasis...!
Sharmin Susiwala
 
Rs pathology 02
Rs pathology 02Rs pathology 02
Rs pathology 02
Ahed Alquraan
 
Rs pathology 02
Rs pathology 02Rs pathology 02
Rs pathology 02
Ahed Alquraan
 
Interstitial Lung Diseases [ILD] Approach to Management
Interstitial Lung Diseases [ILD] Approach to ManagementInterstitial Lung Diseases [ILD] Approach to Management
Interstitial Lung Diseases [ILD] Approach to Management
Arun Vasireddy
 
Lesson 12 - pulmanary diseases_09091017.pptx
Lesson 12 - pulmanary diseases_09091017.pptxLesson 12 - pulmanary diseases_09091017.pptx
Lesson 12 - pulmanary diseases_09091017.pptx
mdaquib14
 
باثوهObstructiveLungDiseaseI-1.pptx
باثوهObstructiveLungDiseaseI-1.pptxباثوهObstructiveLungDiseaseI-1.pptx
باثوهObstructiveLungDiseaseI-1.pptx
TofikMohammed3
 
Pneumonia
PneumoniaPneumonia
Pneumonia
hemin sab
 
Lec 7.ppt
Lec 7.pptLec 7.ppt
Lec 7.ppt
ishanjainmj
 
01.copd
01.copd01.copd
01.copd
Dragon Yott
 
COPD - Chronic Obstructive Pulmonary Disease |medico X| Pathology
COPD - Chronic Obstructive Pulmonary Disease |medico X| PathologyCOPD - Chronic Obstructive Pulmonary Disease |medico X| Pathology
COPD - Chronic Obstructive Pulmonary Disease |medico X| Pathology
Dr. Devkumar Sahu
 
interstitial lung disease (ilD)
interstitial lung disease (ilD)interstitial lung disease (ilD)
interstitial lung disease (ilD)
Mahamad Jamal
 
Cyptogenic orgnaising pneumonia
Cyptogenic orgnaising pneumoniaCyptogenic orgnaising pneumonia
Cyptogenic orgnaising pneumoniaYogesh Girhepunje
 

Similar to Diffuse interstitial (infiltrative, restrictive) diseases. Pathology. mpiloe (20)

L7 8 .interestitial lung disease
L7 8 .interestitial lung diseaseL7 8 .interestitial lung disease
L7 8 .interestitial lung disease
 
Chest x ray interpretation of infections [autosaved]
Chest x ray interpretation of infections [autosaved]Chest x ray interpretation of infections [autosaved]
Chest x ray interpretation of infections [autosaved]
 
ild2-160503173013.pdf
ild2-160503173013.pdfild2-160503173013.pdf
ild2-160503173013.pdf
 
Interstitial Lung Diseases & Pathology Of Lung In AIDS
Interstitial Lung Diseases &Pathology Of Lung In AIDSInterstitial Lung Diseases &Pathology Of Lung In AIDS
Interstitial Lung Diseases & Pathology Of Lung In AIDS
 
DIFFUSE LUNG DISEASES.pptx
DIFFUSE LUNG DISEASES.pptxDIFFUSE LUNG DISEASES.pptx
DIFFUSE LUNG DISEASES.pptx
 
Community acquired pneumonia
Community acquired pneumoniaCommunity acquired pneumonia
Community acquired pneumonia
 
08 respiratory restrictive
08 respiratory   restrictive08 respiratory   restrictive
08 respiratory restrictive
 
Lung pathology 1
Lung pathology 1Lung pathology 1
Lung pathology 1
 
Common suppurative diseases of lung- Bronchiectasis...!
Common suppurative diseases of lung- Bronchiectasis...!Common suppurative diseases of lung- Bronchiectasis...!
Common suppurative diseases of lung- Bronchiectasis...!
 
Rs pathology 02
Rs pathology 02Rs pathology 02
Rs pathology 02
 
Rs pathology 02
Rs pathology 02Rs pathology 02
Rs pathology 02
 
Interstitial Lung Diseases [ILD] Approach to Management
Interstitial Lung Diseases [ILD] Approach to ManagementInterstitial Lung Diseases [ILD] Approach to Management
Interstitial Lung Diseases [ILD] Approach to Management
 
Lesson 12 - pulmanary diseases_09091017.pptx
Lesson 12 - pulmanary diseases_09091017.pptxLesson 12 - pulmanary diseases_09091017.pptx
Lesson 12 - pulmanary diseases_09091017.pptx
 
باثوهObstructiveLungDiseaseI-1.pptx
باثوهObstructiveLungDiseaseI-1.pptxباثوهObstructiveLungDiseaseI-1.pptx
باثوهObstructiveLungDiseaseI-1.pptx
 
Pneumonia
PneumoniaPneumonia
Pneumonia
 
Lec 7.ppt
Lec 7.pptLec 7.ppt
Lec 7.ppt
 
01.copd
01.copd01.copd
01.copd
 
COPD - Chronic Obstructive Pulmonary Disease |medico X| Pathology
COPD - Chronic Obstructive Pulmonary Disease |medico X| PathologyCOPD - Chronic Obstructive Pulmonary Disease |medico X| Pathology
COPD - Chronic Obstructive Pulmonary Disease |medico X| Pathology
 
interstitial lung disease (ilD)
interstitial lung disease (ilD)interstitial lung disease (ilD)
interstitial lung disease (ilD)
 
Cyptogenic orgnaising pneumonia
Cyptogenic orgnaising pneumoniaCyptogenic orgnaising pneumonia
Cyptogenic orgnaising pneumonia
 

Recently uploaded

heat stroke and heat exhaustion in children
heat stroke and heat exhaustion in childrenheat stroke and heat exhaustion in children
heat stroke and heat exhaustion in children
SumeraAhmad5
 
THOA 2.ppt Human Organ Transplantation Act
THOA 2.ppt Human Organ Transplantation ActTHOA 2.ppt Human Organ Transplantation Act
THOA 2.ppt Human Organ Transplantation Act
DrSathishMS1
 
Alcohol_Dr. Jeenal Mistry MD Pharmacology.pdf
Alcohol_Dr. Jeenal Mistry MD Pharmacology.pdfAlcohol_Dr. Jeenal Mistry MD Pharmacology.pdf
Alcohol_Dr. Jeenal Mistry MD Pharmacology.pdf
Dr Jeenal Mistry
 
ARTIFICIAL INTELLIGENCE IN HEALTHCARE.pdf
ARTIFICIAL INTELLIGENCE IN  HEALTHCARE.pdfARTIFICIAL INTELLIGENCE IN  HEALTHCARE.pdf
ARTIFICIAL INTELLIGENCE IN HEALTHCARE.pdf
Anujkumaranit
 
Couples presenting to the infertility clinic- Do they really have infertility...
Couples presenting to the infertility clinic- Do they really have infertility...Couples presenting to the infertility clinic- Do they really have infertility...
Couples presenting to the infertility clinic- Do they really have infertility...
Sujoy Dasgupta
 
Physiology of Chemical Sensation of smell.pdf
Physiology of Chemical Sensation of smell.pdfPhysiology of Chemical Sensation of smell.pdf
Physiology of Chemical Sensation of smell.pdf
MedicoseAcademics
 
The POPPY STUDY (Preconception to post-partum cardiovascular function in prim...
The POPPY STUDY (Preconception to post-partum cardiovascular function in prim...The POPPY STUDY (Preconception to post-partum cardiovascular function in prim...
The POPPY STUDY (Preconception to post-partum cardiovascular function in prim...
Catherine Liao
 
Non-respiratory Functions of the Lungs.pdf
Non-respiratory Functions of the Lungs.pdfNon-respiratory Functions of the Lungs.pdf
Non-respiratory Functions of the Lungs.pdf
MedicoseAcademics
 
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...
Oleg Kshivets
 
BENIGN PROSTATIC HYPERPLASIA.BPH. BPHpdf
BENIGN PROSTATIC HYPERPLASIA.BPH. BPHpdfBENIGN PROSTATIC HYPERPLASIA.BPH. BPHpdf
BENIGN PROSTATIC HYPERPLASIA.BPH. BPHpdf
DR SETH JOTHAM
 
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists  Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists
Saeid Safari
 
POST OPERATIVE OLIGURIA and its management
POST OPERATIVE OLIGURIA and its managementPOST OPERATIVE OLIGURIA and its management
POST OPERATIVE OLIGURIA and its management
touseefaziz1
 
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...
GL Anaacs
 
Charaka Samhita Sutra sthana Chapter 15 Upakalpaniyaadhyaya
Charaka Samhita Sutra sthana Chapter 15 UpakalpaniyaadhyayaCharaka Samhita Sutra sthana Chapter 15 Upakalpaniyaadhyaya
Charaka Samhita Sutra sthana Chapter 15 Upakalpaniyaadhyaya
Dr KHALID B.M
 
How to Give Better Lectures: Some Tips for Doctors
How to Give Better Lectures: Some Tips for DoctorsHow to Give Better Lectures: Some Tips for Doctors
How to Give Better Lectures: Some Tips for Doctors
LanceCatedral
 
BRACHYTHERAPY OVERVIEW AND APPLICATORS
BRACHYTHERAPY OVERVIEW  AND  APPLICATORSBRACHYTHERAPY OVERVIEW  AND  APPLICATORS
BRACHYTHERAPY OVERVIEW AND APPLICATORS
Krishan Murari
 
Antiulcer drugs Advance Pharmacology .pptx
Antiulcer drugs Advance Pharmacology .pptxAntiulcer drugs Advance Pharmacology .pptx
Antiulcer drugs Advance Pharmacology .pptx
Rohit chaurpagar
 
Hemodialysis: Chapter 3, Dialysis Water Unit - Dr.Gawad
Hemodialysis: Chapter 3, Dialysis Water Unit - Dr.GawadHemodialysis: Chapter 3, Dialysis Water Unit - Dr.Gawad
Hemodialysis: Chapter 3, Dialysis Water Unit - Dr.Gawad
NephroTube - Dr.Gawad
 
MANAGEMENT OF ATRIOVENTRICULAR CONDUCTION BLOCK.pdf
MANAGEMENT OF ATRIOVENTRICULAR CONDUCTION BLOCK.pdfMANAGEMENT OF ATRIOVENTRICULAR CONDUCTION BLOCK.pdf
MANAGEMENT OF ATRIOVENTRICULAR CONDUCTION BLOCK.pdf
Jim Jacob Roy
 
micro teaching on communication m.sc nursing.pdf
micro teaching on communication m.sc nursing.pdfmicro teaching on communication m.sc nursing.pdf
micro teaching on communication m.sc nursing.pdf
Anurag Sharma
 

Recently uploaded (20)

heat stroke and heat exhaustion in children
heat stroke and heat exhaustion in childrenheat stroke and heat exhaustion in children
heat stroke and heat exhaustion in children
 
THOA 2.ppt Human Organ Transplantation Act
THOA 2.ppt Human Organ Transplantation ActTHOA 2.ppt Human Organ Transplantation Act
THOA 2.ppt Human Organ Transplantation Act
 
Alcohol_Dr. Jeenal Mistry MD Pharmacology.pdf
Alcohol_Dr. Jeenal Mistry MD Pharmacology.pdfAlcohol_Dr. Jeenal Mistry MD Pharmacology.pdf
Alcohol_Dr. Jeenal Mistry MD Pharmacology.pdf
 
ARTIFICIAL INTELLIGENCE IN HEALTHCARE.pdf
ARTIFICIAL INTELLIGENCE IN  HEALTHCARE.pdfARTIFICIAL INTELLIGENCE IN  HEALTHCARE.pdf
ARTIFICIAL INTELLIGENCE IN HEALTHCARE.pdf
 
Couples presenting to the infertility clinic- Do they really have infertility...
Couples presenting to the infertility clinic- Do they really have infertility...Couples presenting to the infertility clinic- Do they really have infertility...
Couples presenting to the infertility clinic- Do they really have infertility...
 
Physiology of Chemical Sensation of smell.pdf
Physiology of Chemical Sensation of smell.pdfPhysiology of Chemical Sensation of smell.pdf
Physiology of Chemical Sensation of smell.pdf
 
The POPPY STUDY (Preconception to post-partum cardiovascular function in prim...
The POPPY STUDY (Preconception to post-partum cardiovascular function in prim...The POPPY STUDY (Preconception to post-partum cardiovascular function in prim...
The POPPY STUDY (Preconception to post-partum cardiovascular function in prim...
 
Non-respiratory Functions of the Lungs.pdf
Non-respiratory Functions of the Lungs.pdfNon-respiratory Functions of the Lungs.pdf
Non-respiratory Functions of the Lungs.pdf
 
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...
 
BENIGN PROSTATIC HYPERPLASIA.BPH. BPHpdf
BENIGN PROSTATIC HYPERPLASIA.BPH. BPHpdfBENIGN PROSTATIC HYPERPLASIA.BPH. BPHpdf
BENIGN PROSTATIC HYPERPLASIA.BPH. BPHpdf
 
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists  Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists
 
POST OPERATIVE OLIGURIA and its management
POST OPERATIVE OLIGURIA and its managementPOST OPERATIVE OLIGURIA and its management
POST OPERATIVE OLIGURIA and its management
 
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...
 
Charaka Samhita Sutra sthana Chapter 15 Upakalpaniyaadhyaya
Charaka Samhita Sutra sthana Chapter 15 UpakalpaniyaadhyayaCharaka Samhita Sutra sthana Chapter 15 Upakalpaniyaadhyaya
Charaka Samhita Sutra sthana Chapter 15 Upakalpaniyaadhyaya
 
How to Give Better Lectures: Some Tips for Doctors
How to Give Better Lectures: Some Tips for DoctorsHow to Give Better Lectures: Some Tips for Doctors
How to Give Better Lectures: Some Tips for Doctors
 
BRACHYTHERAPY OVERVIEW AND APPLICATORS
BRACHYTHERAPY OVERVIEW  AND  APPLICATORSBRACHYTHERAPY OVERVIEW  AND  APPLICATORS
BRACHYTHERAPY OVERVIEW AND APPLICATORS
 
Antiulcer drugs Advance Pharmacology .pptx
Antiulcer drugs Advance Pharmacology .pptxAntiulcer drugs Advance Pharmacology .pptx
Antiulcer drugs Advance Pharmacology .pptx
 
Hemodialysis: Chapter 3, Dialysis Water Unit - Dr.Gawad
Hemodialysis: Chapter 3, Dialysis Water Unit - Dr.GawadHemodialysis: Chapter 3, Dialysis Water Unit - Dr.Gawad
Hemodialysis: Chapter 3, Dialysis Water Unit - Dr.Gawad
 
MANAGEMENT OF ATRIOVENTRICULAR CONDUCTION BLOCK.pdf
MANAGEMENT OF ATRIOVENTRICULAR CONDUCTION BLOCK.pdfMANAGEMENT OF ATRIOVENTRICULAR CONDUCTION BLOCK.pdf
MANAGEMENT OF ATRIOVENTRICULAR CONDUCTION BLOCK.pdf
 
micro teaching on communication m.sc nursing.pdf
micro teaching on communication m.sc nursing.pdfmicro teaching on communication m.sc nursing.pdf
micro teaching on communication m.sc nursing.pdf
 

Diffuse interstitial (infiltrative, restrictive) diseases. Pathology. mpiloe

  • 2. Obstructive Versus Restrictive Pulmonary Diseases Such a classification is based on pulmonary function tests. A critical part of the initial workup of patients. 1. obstructive disease (airway disease)- limitation of airflow. 2. restrictive disease-reduced expansion of lung parenchyma. Obstructive disease: hallmark is a decreased expiratory flow rate (FEV1 it follows that the ratio of FEV1 to FVC ). Diffuse restrictive diseases FVC is reduced and the expiratory flow rate is normal or reduced proportionately (ratio of FEV1 to FVC is near normal).
  • 3. Focus on restrictive defect Occurs in two general conditions 1. Chest wall disorders in the presence of normal lungs (e.g in diseases of the pleura, Guillain-Barre syndrome. 2. Acute or chronic interstitial lung diseases (classic acute restrictive disease is ARDS, Chronic restrictive diseases pneumoconiosis, interstitial fibrosis of unknown aetiology, and most of the infiltrative conditions (e.g., sarcoidosis). THE SECOND CONDITION IS WHAT WE WILL FOCUS ON.
  • 4. Diffuse Interstitial (Infiltrative, Restrictive) Diseases Heterogeneous group of disorders characterised by diffuse usually chronic involvement of pulmonary connective tissue. Principally the most peripheral and delicate interstitium in alveolar walls
  • 5. DEFINITION cont.… Many of the entities are of unknown cause and pathogenesis. Some have an intra-alveolar as well as an interstitial component. Account for about 15% of non-infectious diseases. Clinical and pulmonary functional changes.  Patients have dyspnoea, tachypnea, end-inspiratory crackles, and eventual cyanosis, without wheezing. Classic physiologic features: reductions in carbon monoxide diffusing capacity, lung volume, and compliance. CXR-picture and the term infiltrative. Early stages-can often be distinguished . Advanced forms- hard to differentiate becoz, of end-stage lung.
  • 6. DEFINITION cont.… Categorized either as clinicopathologic syndromes or as having characteristic histology .  Frequency of disease: most common associations are -Environmental diseases (approximately 25%) -Sarcoidosis (approximately 20%) -Idiopathic pulmonary fibrosis (approximately 15%) -the collagen vascular diseases (approximately 10%) more than 100 different causes and associations account for the remaining interstitial disease.
  • 8. Pathogenesis cont.… Earliest common manifestation of most of the interstitial diseases is alveolitis. In mild and self-limited injury, resolution with restoration of normal architecture follows.  Accumulation of leukocytes has two consequences. -1. Distorts the normal alveolar structures . -2. Release of mediators that can injure parenchymal cells and stimulate fibrosis THESE RESULT IN END STAGE LUNG
  • 9. Pathogenesis cont.… initial stimuli for alveolitis are as heterogeneous, ROS, directly toxic to endothelial cells, epithelial cells etc. Compliment and macrophage mediated accumulation of inflammatory cells is seen I most diseases . CMI is seen in disease like sarcoidosis with formation of granulomas .
  • 10. Major Categories of Chronic Interstitial Lung Disease Fibrosing Usual interstitial pneumonia (idiopathic pulmonary fibrosis) (IPF ) Nonspecific interstitial pneumonia (NSIP) Cryptogenic organizing pneumonia (COP) Associated with collagen vascular diseases Pneumoconiosis Drug reactions Radiation pneumonitis Granulomatous Sarcoidosis Hypersensitivity pneumonitis Eosinophilic Smoking-Related Desquamative interstitial pneumonia Respiratory bronchiolitis-associated interstitial lung disease Other Pulmonary alveolar proteinosis
  • 11. Fibrosing Category 1. Idiopathic Pulmonary Fibrosis (cryptogenic fibrosing alveolitis) Diffuse interstitial fibrosis (usual interstitial pneumonia (UIP)), which in advanced cases results in severe hypoxemia and cyanosis. Males are affected more often than are females. Approx. two-thirds of patients are older than 60 years of age at presentation. similar pathologic findings in the lung may be noted with well-defined entities such as asbestosis
  • 12. Morphology Pleural surfaces of the lung have the appearance of cobblestones . The cut surface shows fibrosis (firm, rubbery white areas). Patchy interstitial fibrosis.  Earliest lesions appear as fibroblastic foci . Temporal heterogeneity. Honeycomb fibrosis occurs. The interstitial inflammation is usually patchy and consists of an alveolar septal infiltrate of mostly lymphocytes .  Foci of squamous metaplasia and Intimal fibrosis and medial thickening of pulmonary arteries often present.
  • 13. Usual interstitial pneumonia. The fibrosis, which varies in intensity, is more pronounced in the sub-pleural region
  • 14. Usual interstitial pneumonia. Fibroblastic focus with fibres running parallel to surface and bluish myxoid extracellular matrix.
  • 15. Clinical Course IPF usually presents insidiously Gradual onset of a non-productive cough and progressive dyspnoea. O/E  "dry" or "Velcro"-like crackles during inspiration. Cyanosis, cor pulmonale, and peripheral oedema . Investigations: Surgical lung biopsy remains the gold standard for diagnosing IPF . Prognosis is poor mean survival of 3 years or less.
  • 16. Nonspecific Interstitial Pneumonia Unknown aetiology, affects mostly 45 to 55 year olds. Lung biopsies fail to show diagnostic features of any of the other well- characterized interstitial diseases. "wastebasket" type of diagnosis, it is important to differentiate non- specific interstitial fibrosis from UIP. Divided into cellular and fibrosing patterns. Fibroblastic foci are typically absent. Clinical course : Patients present with dyspnoea and cough of several months' duration cellular pattern have a better outcome
  • 17. Cryptogenic Organizing Pneumonia Synonymous with "bronchiolitis obliterans organizing pneumonia. Clinical course cough and dyspnoea .  Radiographically have subpleural or peribronchial patchy areas of airspace consolidation Some individuals recover spontaneously, but most require treatment Histologically Polypoid plugs of loose organizing connective tissue within alveolar ducts, alveoli, and often bronchioles . Organizing pneumonia with intra-alveolar fibrosis.  There is no interstitial fibrosis/ honeycomb
  • 18. Cryptogenic organizing pneumonia. Alveolar spaces are filled with balls of fibroblasts (arrow).
  • 19. Pulmonary Involvement in Collagen Vascular Diseases systemic lupus erythematous, rheumatoid arthritis, systemic sclerosis, and dermatomyositis-polymyositis are examples. Histologic variants , with NSIP, UIP-pattern (similar to what is seen in IPF), vascular sclerosis, organizing pneumonia, and bronchiolitis (small airway disease, with or without fibrosis) being the most common. Pulmonary involvement in these diseases is usually associated with a poor prognosis.
  • 20. Pneumoconiosis Non neoplastic lungs reaction to inhalation of mineral dusts in the work place and organic as well as inorganic particles, fumes and vapours.
  • 21. Mineral Dust-Induced Lung Disease  Agent Disease: Exposure Coal dust exposure: Simple coal workers' pneumoconiosis: macules and nodules Complicated coal workers' pneumoconiosis: PMF- Coal mining Silica exposure: Silicosis -Sandblasting, quarrying, mining, stone cutting, foundry work, ceramics Asbestos exposure: Asbestosis pleural effusions, pleural plaques, or diffuse fibrosis; mesothelioma; carcinoma of the lung and larynx- Mining, milling, and fabrication of ores and materials; installation and removal of insulation
  • 22. Pathogenesis Size, shape, solubility, and reactivity of the particles etc determine the reaction of the lung to mineral dusts . The amount which cause disease depends on the factors above. Coal dust is relatively inert (large amounts must deposit). Silica, asbestos, and beryllium are more reactive than coal dust (fibrotic reactions at lower concentrations) Macrophages accumulate and endocytose the trapped particulates More reactive particles trigger the macrophages to release inflammatory mediators. Tobacco smoking worsens the effects of all inhaled mineral dusts, more so with asbestos than with any other particle.  Larger particles resist dissolution these tend to evoke fibrosing collagenous pneumoconiosis (characteristic of silicosis).
  • 23. Coal Workers' Pneumoconiosis ("black lung" ) Findings range from: 1.asymptomatic anthracosis, 2.simple coal workers' pneumoconiosis (CWP),3. complicated CWP or progressive massive fibrosis (PMF). Fewer than 10% of cases of simple CWP progress to PMF. PMF is a generic term that applies to a confluent fibrosing reaction in the lung; this can be a complication of any one of the three pneumoconiosis discussed here. Anthracite mining has been associated with a higher risk of CWP.
  • 24. Morphology Pulmonary anthracosis: innocuous coal-induced pulmonary lesion -Inhaled carbon pigment is engulfed by alveolar or interstitial macrophages. -Which then accumulate in the connective tissue along the lymphatics, including the pleural lymphatics, or in lymph nodes. Linear streaks and aggregates of anthracotic pigment are seen. Simple CWP: coal macules and the somewhat larger coal nodule are seen. -The upper lobes and upper zones of the lower lobes are more heavily involved.C -Centrilobular emphysema can occur. Complicated CWP (PMF) Occurs on a background of simple CWP by coalescence of coal nodules characterized by intensely blackened scars larger than 2 cm, sometimes up to 10 cm in greatest diameter
  • 25. Progressive massive fibrosis superimposed on coal workers' pneumoconiosis. The large blackened scars are principally in the upper lobe. Note the extensions of scars into surrounding parenchyma and retraction of adjacent pleura.
  • 26. Clinical Course  Usually a benign disease that produces little decrement in lung function. Increasing pulmonary dysfunction, pulmonary hypertension, and cor pulmonale, seen if PMF develops.  Progression from CWP to PMF has been linked to a variety of conditions including coal dust exposure level and total dust burden  Once smoking-related risk has been taken into account, there is no increased frequency of bronchogenic carcinoma in coal miners.
  • 27. Silicosis Currently the most prevalent chronic occupational disease in the world. Slowly progressive. Caused by inhalation of crystalline silica.(quartz is most commonly implicated in silicosis) After inhalation the particles interact with epithelial cells and macrophages. Ingested silica particles cause activation and release of mediators by pulmonary macrophages, including IL-1, TNF. When mixed with other minerals, quartz has a reduced fibrogenic effect.
  • 28. Morphology Silicotic nodules . Microscopically, the silicotic nodule demonstrates concentrically arranged hyalinized collagen fibers surrounding an amorphous center. "whorled" appearance of the collagen fibres. Polarized microscopy reveals weakly birefringent silica particles, primarily in the center of the nodules. Fibrotic lesions may occur in the hilar lymph nodes and pleura. "eggshell" calcification .
  • 29. Advanced silicosis seen on transection of lung. Scarring has contracted the upper lobe into a small dark mass (arrow). Note the dense pleural thickening
  • 30. Several coalescent collagenous silicotic nodules
  • 31. Clinical Course Usually detected in routine chest radiographs performed on asymptomatic workers.(fine nodularity in the upper zones of the lung is seen) After PMF is present the disease may be progressive, even if the person is no longer exposed. Many individuals with PMF develop pulmonary hypertension and cor pulmonale, Disease is slow to kill, but impaired pulmonary function may severely limit activity. Silicosis is associated with an increased susceptibility to tuberculosis.
  • 32. Asbestosis and Asbestos-Related Diseases occupational exposure to asbestos is linked to : (1) parenchymal interstitial fibrosis (asbestosis) (2) localized fibrous plaques or, rarely, diffuse fibrosis in the pleura (3) pleural effusion (4) bronchogenic carcinoma. (5) malignant pleural and peritoneal mesothelioma (6) laryngeal carcinoma.
  • 33. Pathogenesis There are two distinct forms of asbestos Serpentine and amphibole. Amphibole are more pathogenic than the serpentine chrysotile. Asbestos causes fibrosis by interacting with lung macrophages. Asbestos probably also functions as both a tumor initiator and a promoter. Potentially toxic chemicals adsorbed onto the asbestos fibers undoubtedly contribute to the pathogenicity of the fibres.
  • 34. Morphology  Marked by diffuse pulmonary interstitial fibrosis. Asbestos bodies distinguish it from diffuse interstitial fibrosis.  Asbestosis begins in the lower lobes and subpleurally ( In contrast to CWP and silicosis)  Contraction of the fibrous tissue distorts the native architecture, creating enlarged airspaces enclosed within thick fibrous walls.(honeycombed formation). Pulmonary hypertension and cor pulmonale may result. Pleural plaques (well-circumscribed plaques of dense collagen often containing calcium.) Uncommonly, asbestos exposure induces pleural effusions, which are usually serous but may be bloody.
  • 35. High-power detail of an asbestos body, revealing the typical beading and knobbed ends (arrow)
  • 36. Asbestosis. Markedly thickened visceral pleura covers the lateral and diaphragmatic surface of lung. Note also severe interstitial fibrosis diffusely affecting the lower lobe of the lung
  • 37. Clinical Course Dyspnea (exertion then at rest) Productive cough The disease may remain static or progress to CHF, cor pulmonale, and death Disease manifestations more common 20 years after exposure. The relative risk for mesotheliomas, normally a very rare tumor , is more than 1000-fold greater. Concomitant cigarette smoking, has no association with increased risk of mesothelioma.
  • 38. Drug- and Radiation-Induced Pulmonary Diseases Acute and chronic alterations in respiratory structure and function can result from drugs.e.g Bleomycin, an anticancer agent, causes pneumonitis and interstitial fibrosis Amiodarone, an anti-arrhythmic agent, is also associated with pneumonitis and fibrosis  Radiation pneumonitis . Acute radiation pneumonitis-fever, dyspnea out of proportion to the volume of irradiated lung, pleural effusion, and pulmonary infiltrates. Progress to chronic radiation pneumonitis may occur, associated with pulmonary fibrosis.
  • 39. Granulomatous Diseases Sarcoidosis -bilateral hilar lymphadenopathy or lung involvement (or both), visible on chest radiographs, is the major presenting manifestation . The prevalence of sarcoidosis is higher in women than in men, BLACKS than whites . Sarcoidosis is one of the few pulmonary diseases with a higher prevalence among nonsmokers.
  • 40. Aetiology and Pathogenesis Unknown but evidence points to the1. immune dysregulation in 2. genetically predisposed individual 3. exposed to certain environmental agents Cell mediated response to unidentified antigen driven by CD4= helper T cells. CMI. These accumulate In the Intra-alveolar and interstitial space.  IL -2 and IFN-GAMMA etc from TH-1 cells, result in T-cell expansion and macrophage activation, respectively, this eventually lead to recruitment of additional T cells and monocytes and contribute to the formation of granulomas. Polyclonal hypergammaglobulinemia and anergy to common skin test antigens occur. (TH-cell dysregulation) Familial and racial clustering of cases and association with certain human leukocyte antigen (HLA) genotypes (e.g., class I HLA-A1 and HLA-B8)  Viruses, mycobacteria, Borrelia, pollen have been proposed as the inciting agent for sarcoidosis .
  • 41. Morphology noncaseating epithelioid granuloma. Central necrosis unusual Granulomatous fibrous and hyaline with chronicity. Schaumann bodies and Asteroid bodies are also seen (not pathognomonic of sarcoidosis) . The granulomas predominantly involve the interstitium rather than airspaces, with some "lymphangitic" distribution tendency. The bronchoalveolar lavage (BAL) contains abundant CD4+T cells. Diffuse interstitial fibrosis resulting in a honeycomb lung in 5-15%. hilar and paratracheal lymph nodes are enlarged in 75% to 90% of patients.
  • 42. Morphology cont… Skin lesions : approximately 30-50% of cases of patients. -Erythema nodosum, the hallmark of acute sarcoidosis ( Sarcoidal granulomas are uncommon in these lesions). -Lupus pernio. Involvement of the eye and lacrimal glands occurs in about one-fifth to one-half of patients -ocular involvement: takes the form of iritis or iridocyclitis (Corneal opacities, glaucoma, and (less commonly) total loss of vision may then develop. -Posterior uveal tract is also affected. -Ocular lesions are frequently accompanied by inflammation in the lacrimal glands sicca syndrome may occur.. Unilateral or bilateral parotitis with painful enlargement of the parotid glands in < 10%.  Mikulicz syndrome, is also seen.
  • 43. Morphology cont… -The spleen In about three-fourths of cases it contains granulomas, in approximately 10% it becomes clinically enlarged.  The liver demonstrates microscopic granulomatous lesions, usually in the portal triads. Bone marrow is reported in as many as 40% of patients, although it rarely causes severe manifestations. Sometimes there is hypercalcemia and hypercalciuria. Muscle involvement : is often underdiagnosed, since it may be asymptomatic. muscle weakness, aches, tenderness, and fatigue should prompt consideration of occult sarcoid myositis. Muscle biopsy could be a useful tool in the diagnosis of sarcodosis.
  • 44. Characteristic sarcoid noncaseating granulomas in lung with many giant cells
  • 45. Clinical Course. In many individuals the disease is entirely asymptomatic, discovered on routine chest films . bilateral hilar adenopathy or as an incidental finding at autopsy In others, lesion to other tissues may be presenting manifestations. In about two-thirds of symptomatic cases there is a gradual appearance of respiratory symptoms . Lung or lymph node biopsy are often used. Sarcoidosis follows an unpredictable course . 65% to 70% of affected individuals recover with minimal or no residual manifestations. 20% develop permanent lung dysfunction or visual impairment. Of the remaining 10% to 15%, most succumb to progressive pulmonary fibrosis and cor pulmonale. Patients presenting with hilar lymphadenopathy alone have the best prognosis, followed by those with adenopathy and pulmonary infiltrates.
  • 46. Hypersensitivity Pneumonitis An immunologically mediated inflammatory lung disease (allergic alveolitis). Results from heightened sensitivity to inhaled antigens such as moldy hay . Immunologically mediated injury occurs at the level of alveoli. Occupational exposures are diverse, probably have very similar pathophysiology. Several lines of evidence suggest that hypersensitivity pneumonitis is an immunologically mediated disease. Increased numbers of T lymphocytes of both CD4+ and CD8+ phenotype, also indication of a type III hypersensitivity and type IV hypersensitivity against the implicated antigen(s). hypersensitivity pneumonitis is an immunologically mediated response to an extrinsic antigen that involves both immune-complex and delayed-type hypersensitivity reactions. progression to serious chronic fibrotic lung disease can be prevented by removal of the environmental agent.
  • 47. Selected Causes of Hypersensitivity Pneumonitis Syndrome – Exposure - Antigens Fungal and Bacterial Antigens -Farmer's lung - Moldy hay - Micropolyspora faeni . -Bagassosis - Moldy pressed sugar cane (bagasse ) - Thermophilic actinomycetes. -Maple bark disease - Moldy maple bark - Cryptostroma corticale . -Humidifier lung - Cool-mist humidifier -Thermophilic actinomycetes, Aureobasidium pullulans -Malt worker's lung - Moldy barley - Aspergillus clavatus . -Cheese washer's lung - Moldy cheese - Penicillium casei . Insect Products -Miller's lung - Dust-contaminated grain - Sitophilus granarius (wheat weevil) . Animal Products -Pigeon breeder's lung - Pigeons - Pigeon serum proteins in droppings . Chemicals -Chemical worker's lung - Chemical industry - Trimellitic anhydride, isocyanates .
  • 48. Morphology Patchy mononuclear cell infiltrates, demonstrated in both acute and chronic forms of hypersensitivity pneumonitis.  Lymphocytes predominate, but plasma cells and epithelioid cells are also present. In acute forms of the disease, variable numbers of neutrophils also may be seen. Interstitial noncaseating granulomas are present in more than two-thirds of cases. In advanced chronic cases, diffuse interstitial fibrosis occurs. Interstitial fibrosis and obliterative bronchiolitis (late stages) Intra-alveolar infiltrates in over 50%
  • 49. Hypersensitivity pneumonitis, histologic appearance. Loosely formed interstitial granulomas and chronic inflammation are characteristic.
  • 50. Clinical Course May present either : As a may present either as an acute reaction with fever, cough, dyspnea, and constitutional complaints 4 to 8 hours after exposure . As a chronic disease with insidious onset of cough, dyspnea, malaise, and weight loss. Temporal relationship of symptoms to exposure to the incriminating antigen in acute rxn makes diagnosis obvious.
  • 51. Pulmonary Eosinophilia These diverse diseases are generally of immunologic origin but are incompletely understood . characterized by an infiltration and activation of eosinophils, the latter by elevated levels of alveolar IL-5. Pulmonary eosinophilia is divided into the following categories: 1. Acute eosinophilic pneumonia with respiratory failure. -characterized by: rapid onset of fever, dyspnea, hypoxia, and diffuse pulmonary infiltrates on chest radiograms. 2. Simple pulmonary eosinophilia (Löffler syndrome). -characterized by transient pulmonary lesions, eosinophilia in the blood, and a benign clinical course. -The alveolar septa are thickened by an infiltrate containing eosinophils and occasional giant cells
  • 52. Pulmonary Eosinophilia 3. Tropical eosinophilia -caused by infection with microfilariae, a parasite. 4. Secondary eosinophilia, - Seen, for example, in association with asthma, drug allergies, and certain forms of vasculitis. 1.Idiopathic chronic eosinophilic pneumonia. -Characterized by aggregates of lymphocytes and eosinophils within the septal walls and the alveolar spaces, typically in the periphery of the lung fields . -accompanied by high fever, night sweats, and dyspnea. -Good response to corticosteroids
  • 53. Smoking-Related Interstitial Diseases Desquamative interstitial pneumonia (DIP) and respiratory bronchiolitis are the two eg. Accumulation of large numbers of macrophages with abundant cytoplasm containing dusty brown pigment (Smoker's macrophages ) in the airspaces in DIP. - The alveolar septa are thickened by a sparse inflammatory infiltrate (usually lymphocytes), and interstitial fibrosis, when present, is mild. - good prognosis with excellent response to steroid therapy and smoking cessation. Respiratory bronchiolitis . characterized by the presence of pigmented intraluminal macrophages akin to DIP, but in a "bronchiolocentric" distribution (first- and second-order respiratory bronchioles).
  • 54. Clinical course DIP presents in the fourth or fifth decade of life, more common males than females 2 : 1. Virtually all patients are cigarette smokers.
  • 55. Desquamative interstitial pneumonia. Medium-power detail of lung to demonstrate the accumulation of large numbers of mononuclear cells within the alveolar spaces with only mild fibrous thickening of the alveolar walls
  • 56. PULMONARY ALVEOLAR PROTEINOSIS Pulmonary alveolar proteinosis (PAP) is a rare disease Characterized : -Radiologically by bilateral patchy asymmetric pulmonary opacification . -Histologically by accumulation of acellular surfactant in the intra-alveolar and bronchiolar spaces.  Three distinct classes of this disease. acquired, congenital, and secondary PAP. 1. Acquired PAP is of unknown etiology. -Without any familial predisposition; it represents 90% of all cases of PAP. -Now considered to be autoimmune disorder and can occur post double lung transplant 2. Congenital PAP is a rare cause of immediate-onset neonatal respiratory distress. -Cause unclear
  • 57. PULMONARY ALVEOLAR PROTEINOSIS 1. Secondary Uncommon Causes include acute silicosis Other inhalational syndromes Immunodeficiency disorders Malignancy  Hematopoietic disorders
  • 58. Morphology. Characterized by a peculiar homogeneous, granular precipitate within the alveoli. Minimal inflammatory reaction Causing focal-to-confluent consolidation of large areas of the lungs with minimal inflammatory reaction. On section, turbid flud exudes from these areas. Marked increase in the size and weight of the lung
  • 59. Pulmonary alveolar proteinosis, histologic appearance. The alveoli are filled with a dense, amorphous, protein-lipid granular precipitate, while the alveolar walls are normal.

Editor's Notes

  1. 10
  2. 16
  3. 17
  4. 19
  5. 20
  6. 21
  7. 22
  8. 23
  9. 24
  10. 26
  11. 27
  12. 28
  13. 31
  14. 33
  15. 34
  16. 37
  17. 38
  18. 39
  19. 40
  20. 41
  21. 42
  22. 43
  23. 45
  24. 46
  25. 47
  26. 48
  27. 50
  28. 51
  29. 52
  30. 53
  31. 55
  32. 56